Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

McLean Hospital and Repligen announce results of brain imaging study of secretin

01.11.2002


Secretin is active in a brain region implicated in autism



Researchers from the Brain Imaging Center at McLean Hospital and Repligen Corporation (Nasdaq: RGEN) reported today the results of a clinical trial designed to assess the neurological activity of secretin by functional magnetic resonance imaging (fMRI). The results demonstrate for the first time in humans, that secretin is active in the central nervous system and that it potentiates activity in the amygdala, a region of the brain involved in social integration and implicated in autism. The findings were presented today by Deborah Yurgelun-Todd, Ph.D., of McLean Hospital, the study’s Principal Investigator, at the International Meeting for Autism Research, a satellite meeting of the Society for Neuroscience.

"Our results demonstrate for the first time that secretin is a neuroactive peptide in humans and that it acts on a brain region known to be important for social interaction," stated Yurgelun-Todd, Director of Cognitive Neuroimaging at the Brain Imaging Center at McLean Hospital. "These findings suggest that secretin may have a role in modulating certain social behavior in humans."


The study was a double-blind, placebo-controlled clinical trial in 12 healthy men. Each subject was presented with a series of pictures of faces with either a neutral, happy or fearful facial expression to establish a baseline response. Following an injection of either secretin or a placebo, the subjects were again presented with the series of facial expressions. Throughout the experiment, the activation of the amygdala was recorded with MRI. There was a significant activation (p=0.001) of the right amygdala by secretin when the subjects viewed pictures of a fearful face compared to both the placebo group and the baseline response to the pictures in the secretin group. By contrast, there was no difference in amygdala activation when subjects viewed pictures of neutral or happy faces. Failure to activate the amygdala when viewing fearful faces is a characteristic of people with autism and patients with amygdala damage. The current study was initiated as part of ongoing research efforts to understand secretin as a neurologically active peptide. Repligen previously reported a finding that treatment of rats with secretin specifically activates the neurons in the amygdala. Repligen is currently developing secretin for autism in a Phase 3 clinical trial program.

"These studies show that secretin is active in a part of the human brain involved in social interaction and potentiates its activity during a social task known to be difficult for people with autism," stated Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen Corporation. "These data provides a plausible biological mechanism for the improvements in social interaction we observed in our Phase 2 clinical trial."

The Amygdala and the Social Deficits of Autism

The amygdala is part of a complex neural system that is critical for ascribing emotional value to stimuli and influencing affective responsiveness and emotional learning. One of the core deficits of autism is impaired reciprocal social interaction, including eye contact, joint attention and an inability to deduce the mental states of others from facial expressions. Reduced activation of the amygdala in patients with autism has been documented using fMRI with specific impairment noted in their ability to respond to facial expressions of fear. Other studies indicate that patients with either surgical or congenital amygdala damage show similar face recognition defects. Lack of activation of the amygdala is recognized as an important correlate of the social deficits of autism.

Repligen’s President and CEO Walter C. Herlihy, Ph.D. also presented data from its Phase 2 clinical trial. The Phase 2 study evaluated three administrations of secretin or a placebo in 126 patients aged 3 years to 6 years 11 months with moderate to severe symptoms of autism and gastrointestinal disorders. The primary finding of the Phase 2 clinical trial was that younger children, 3 and 4 year olds, showed improvements in reciprocal social interaction as judged by a standardized clinical instrument for the assessment of autistic symptoms. Repligen is currently conducting a Phase 3 clinical trial of secretin for the improvement of reciprocal social interaction in young children with autism.


About McLean Hospital
McLean Hospital maintains the largest research program of any private, U.S. psychiatric hospital. It is the largest psychiatric teaching facility of Harvard Medical School, an affiliate of Massachusetts General Hospital and a member of Partners HealthCare. The Brain Imaging Center at McLean is one of the largest imaging centers in the world, actively engaged in clinical research studies of brain function. Researchers at McLean were part of the team that first identified regional abnormalities in brain activation in patients with schizophrenia and in normal aging, as well as regional changes in blood flow and metabolism in patients with Alzheimer’s disease.

About Repligen Corporation
Repligen Corporation is a biopharmaceutical company committed to being the leader in the development of new drugs for pediatric developmental disorders including autism, immune and metabolic disorders. Repligen has a specialty pharmaceuticals business comprised of rProtein ATM and SecreFloTM, the profits from which will be used to support the development of our proprietary products. rProtein ATM is a consumable reagent used by the pharmaceutical industry to produce a class of drugs called monoclonal antibodies and SecreFloTM, secretin for injection, is marketed to gastroenterologists for pancreatic assessment. Repligen’s corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

Renee L. Connolly | EurekAlert!

More articles from Health and Medicine:

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

A big nano boost for solar cells

18.01.2017 | Power and Electrical Engineering

Glass's off-kilter harmonies

18.01.2017 | Materials Sciences

Toward a 'smart' patch that automatically delivers insulin when needed

18.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>